Biliary tract cancers, including intrahepatic, perihilar, and extrahepatic cholangiocarcinoma and gallbladder cancer, are among the most aggressive gastrointestinal malignancies. Treatment options ...

Tovecimig combined with paclitaxel showed a 17.1% response rate in biliary tract cancer, outperforming paclitaxel alone. The COMPANION-002 study reported lower progressive disease rates with tovecimig ...

Please provide your email address to receive an email when new articles are posted on . The addition of durvalumab to gemcitabine and cisplatin significantly extended OS among patients with advanced ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted accelerated approval to zanidatamab-hrii for treatment of adults with previously treated ...

SEOUL, South Korea, Dec. 23, 2025 /PRNewswire/ -- Lunit (KRX: 328130) , a leading provider of AI for cancer diagnostics and precision oncology, today announced that a new study evaluating its ...

Zanidatamab-hrii received FDA accelerated approval for HER2-positive biliary tract cancer, showing a 52% objective response rate in the HERIZON-BTC-01 trial. Biliary tract cancers represent 3% of ...

There has not been a change in the standard of care in this type of cancer in a decade, according to an expert from ASCO. Pairing durvalumab (Imfinzi) with the chemotherapy combination gemcitabine and ...

Tinengotinib (TT-00420) in combination with atezolizumab in Chinese patients (pts) with biliary tract carcinoma (BTC): Preliminary efficacy and safety results from a phase Ib/II study. This is an ASCO ...

TOKYO, Sept 24, 2024 - (JCN Newswire) - - Anticancer Agent "Tasfygo(R) Tablets 35mg" (Tasurgratinib Succinate) Approved in Japan for Biliary Tract Cancer with FGFR2 Gene Fusions or Rearrangements ...